A5: Distributed pathogen and damage detection

The native immune system is the gold standard for pathogen and damage detection — exquisitely sensitive, broadly programmable through somatic hypermutation generating ~10¹¹ distinct B-cell receptor variants per person, and operating continuously throughout the body with no external power requirement. Engineered detection systems are not going to beat it at its own game.

Where engineered systems add value is in three specific gaps the native immune system has.

Response time: engineered detectors can fluoresce or release reporter molecules within minutes of binding their target. Adaptive immunity takes 5-10 days to mount a specific response against a novel pathogen; even innate immunity often takes hours to produce signals detectable in blood (CRP, procalcitonin). For acute conditions where minutes matter (sepsis is the canonical example), engineered detection is meaningfully faster than the native response.

Programmable specificity: engineered detectors can be designed to detect targets the immune system would never naturally recognise — synthetic toxins, defined cancer mutations not yet immunogenic, specific drug metabolites for therapeutic monitoring, environmental pollutants. The immune repertoire is biased toward what evolution has seen; engineered detection can address anything we can characterise molecularly.

Externalised reporting: the immune system signals via cytokines, antibody titres, and cellular changes — all of which require lab tests to characterise. Engineered detectors can produce signals readable by external instruments without sample extraction, allowing diagnosis before symptom emergence and continuous monitoring rather than discrete sampling.

The risks are immune interference — engineered cells can themselves be attacked by the native immune system, can disrupt local immune coordination, and can occasionally transform into autoimmune trigger sources. Practical AIHS designs use engineered detectors as a focused complement to native immunity, not a replacement.

Three categories are particularly stubborn.

Slow-replicating intracellular pathogens (latent herpesviruses, Mycobacterium tuberculosis in dormant state, prions in early infection) replicate too slowly to produce detectable extracellular signal until the infection is well-established. Latent HIV reservoirs are the canonical example: they exist in long-lived memory T cells at very low frequency, produce essentially no viral protein, and are invisible to current detection methods even though we know they're there. By the time the pathogen becomes detectable, it has already disseminated.

Pathogens that mimic host molecules evade molecular pattern recognition. Some helminths (parasitic worms) coat themselves in host glycans. Certain bacteria (group B streptococcus, some pathogenic E. coli) display sialic acid on their surfaces that the immune system reads as "self." Tumour cells frequently display normal-tissue antigens at near-normal levels, making cancer surveillance harder than infection surveillance.

Genuinely novel pathogens — engineered organisms, newly-emerged zoonoses, synthetic biological agents — cannot be detected by systems programmed for known threat classes. They require general damage-and-anomaly detection rather than specific pathogen detection. This is why the DARPA Pandemic Prevention Platform and similar programmes emphasise broad-spectrum sensing over targeted assays.

Prions remain particularly difficult: they are pure protein with no nucleic acid signature, replicate by inducing misfolding rather than synthesising new molecules, and only become detectable when they form aggregates large enough to trigger downstream damage signals — by which point the disease is already established. (For the conceptual ladder from real prions to fictional protomolecule-like agents, see the Institute's learning module M-Bio-01.)

Damage detection relies on damage-associated molecular patterns (DAMPs) — molecules normally hidden inside cells that are released into the extracellular environment when cells are damaged, stressed, or die in non-physiological ways. The native immune system uses pattern recognition receptors (TLR4, RAGE, NLR-family proteins) to detect these signals and initiate inflammation.

Canonical DAMPs include HMGB1 (high-mobility group box 1, released from necrotic but not apoptotic cells), ATP (released by stressed cells, signalling through P2X7 receptors), uric acid (from damaged DNA breakdown), mitochondrial DNA and N-formyl peptides (released from disrupted mitochondria, which the immune system reads as bacterial since mitochondria are evolutionarily bacterial), and various heat shock proteins (released under cellular stress).

Engineered detection can extend the DAMP repertoire and provide more specific damage classification — distinguishing mechanical damage from chemical injury from ischaemic damage, each of which produces different DAMP signatures. Specific candidate engineered sensors include Piezo channel-based mechanical stress detectors (Piezo1 and Piezo2 are mechanosensitive ion channels with well-characterised activation thresholds), HIF-pathway hypoxia sensors (HIF-1α stabilisation as a readout of oxygen deficit), redox-sensitive fluorescent proteins (roGFP variants) for reactive oxygen species detection, and calcium dynamics reporters for cellular activation states.

The integration challenge is correlating DAMP signals with location and cell type to produce actionable damage assessment rather than diffuse alarm. This is where A5 connects directly to A1 (in vivo cellular readout for localising the source of DAMP signals) and A2 (whole-body mapping for tracking damage propagation). Damage signals are only useful if they can be localised to the tissue producing them.